 




<CFRNO>21 CFR Part 343</CFRNO>



<RINDOCK>[Docket No. 94N0255]</RINDOCK>


Over-the-Counter Marketing of Internal Analgesic, Antipyretic, and Antirheumatic Drug Products; Background
Document for Advisory Committee Meeting; Availability; Establishment of a Public Docket and Request for Comments



<AGENCY>
AGENCY: 

Food and Drug Administration, HHS.


</AGENCY>
<ACTION>
ACTION: 

Availability of background document; establishment of a public docket and request for comments.
 



</ACTION>
<SUMMARY>
SUMMARY: 

The Food and Drug Administration is announcing the availability of a background document for the joint meeting of
the Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee on effectiveness data requirements
and labeling for over-the-counter (OTC) marketing of internal analgesic, antipyretic and antirheumatic drug products
scheduled for September 8 and 9, 1994. The background information is being made available to ensure that all interested
parties are aware of the issues that are the subject of the committee discussion. FDA is also announcing that it is establishing
a public docket for comments, views, and other information submitted to the agency on these subjects from interested
persons.


</SUMMARY>
<DATE>
DATES: 

Submit written comments by August 15, 1994 , in order for written comments to be considered for discussion at the September
8 and 9, 1994, advisory committee meeting.


</DATE>
<ADDRESS>
ADDRESSES: 

Submit written comments or relevant data and requests for single copies of the background document to the Dockets
Management Branch (HFA305), Food and Drug Administration, rm. 123, 12420 Parklawn Dr., Rockville,
MD 20857. Comments and requests should be identified with the docket number found in the brackets in the heading of
this document. Send two self-addressed adhesive labels to assist the branch in processing your requests. Three copies
of written comments should be submitted, except that individuals may submit one copy. The background document and
received comments are available for public examination at the Dockets Management Branch (address above), between
9 a.m. and 4 p.m., Monday through Friday.


</ADDRESS>
<FURTHER>
FOR FURTHER INFORMATION CONTACT: 

Lee L. Zwanziger, Center for Drug Evaluation and Research (HFD9), Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 3014434695.


</FURTHER>
<SUPPLEM>
SUPPLEMENTARY INFORMATION: 

In the 

Federal Register

 of July 11, 1994 (59 FR 35375), FDA announced that a forthcoming joint meeting of the Nonprescription Drugs Advisory
Committee and the Arthritis Advisory Committee on effectiveness data requirements and labeling for over-the-counter
(OTC) marketing of internal analgesic, antipyretic and antirheumatic drug products will be held on September 8 and
9, 1994. FDA is holding this meeting to discuss:


(1) Data requirements to support specific types of indications for OTC analgesic drug products;
(2) Recommendations for labeling indications for OTC analgesics; and
(3) The current state of scientific knowledge in the areas of pain receptors, mechanism(s) of pain perception, and
the basis for response to analgesic drug classes.


The purpose of this meeting is to address specific topics and questions contained in the background document that
could result in future rulemaking.



FDA has established public docket No. 94N0255 to enable interested persons to submit comments or other relevant
data on the background document.




Dated: July 15, 1994.

</SUPPLEM>
<SIGNER>
 Michael R. Taylor,

</SIGNER>
<SIGNJOB>
 Deputy Commissioner for Policy.

</SIGNJOB>
<FRFILING>
[FR Doc. 9417811 Filed 72194; 8:45 am]

</FRFILING>
<BILLING>
BILLING CODE 416001F
</BILLING>

